Product Reports Resources Pricing Login Book a demo

Cartesian Therapeutics

Biotech & Life Sciences · Gaithersburg, United States · Founded 2016 · IPO 2023

Cartesian | Developing potent, safer cell and gene therapies for cancer and autoimmune diseases - Cartesian MoreLess

Cartesian Therapeutics is a fully integrated, clinical-stage biopharmaceutical company focused on developing novel cell and gene immunotherapies. These therapies are designed to treat a range of conditions including cancer, autoimmune diseases, and respiratory diseases. Founded in 2016, the company operates in the biotechnology sector and serves patients who are in need of advanced therapeutic options. Cartesian Therapeutics combines discovery, cGMP manufacturing, and clinical operations under one roof, ensuring a streamlined process from research to patient care. The business model revolves around the development and clinical testing of its proprietary therapies, which are then licensed or sold to larger pharmaceutical companies. Revenue is generated through these partnerships, as well as through grants and research funding. The company is currently engaged in multiple active clinical trials aimed at validating the efficacy and safety of its treatments.

Keywords: cell therapy, gene therapy, cancer treatment, autoimmune diseases, respiratory diseases, biopharmaceutical, clinical trials, cGMP manufacturing, immunotherapy, biotechnology.

Valuation $122M
Revenue $2.8M
Total funding $0–10M

Talent graph

Cartesian Therapeutics's talent

Book a demo to see the people
Employees mapped 92 incl. 1 AI specialist
Founders Hidden — book a demo/100 quality score
Key operators 19 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

7 investors on Cartesian Therapeutics's cap table

Sourced from Dealroom's funding and investor records.

Seed 1 investor entered at this stage
National Heart, Lung, and Blood Institute
Series A 1 investor entered at this stage
Schooner Capital
Series B+ 5 investors entered at this stage
Timothy A. Springer
HBM Healthcare Investments
Invus
Surveyor Capital
K2 HealthVentures

Global footprint

Where Cartesian Therapeutics has talent and traffic

Workforce by country
2 countries with
team presence
🇺🇸 United States98.5%
🇬🇧 United Kingdom1.5%
2 countries shown
Web traffic by country
5.9K monthly visits
across markets
🇺🇸 United States79.7%
🇬🇧 United Kingdom13.6%
🇮🇳 India8.5%
Top 3 markets shown

Patent intelligence

$165M patent portfolio · 43 active families

Estimated portfolio value
$165M
134.7% of market cap · comparable to top peer CureVac ($146M)
43 active patent families
Where Cartesian Therapeutics innovates AntigenAntigen specificBiochemistryIMMUNE SUPPRESSANTSImmunology

Where Cartesian Therapeutics concentrates vs peers

Each axis is a top-10 topic across Cartesian Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Cartesian Therapeutics

An AI-synthesized read of the highest-engagement posts about Cartesian Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Cartesian Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.